Jacob Newton Stein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jacob Newton Stein has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer Elston Lafata
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
4 shared publications - Marjory Charlot
Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Chapel Hill North Carolina USA
3 shared publications - William A. Wood
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
3 shared publications - Alan C. Kinlaw
University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC
2 shared publications - Alexis C. Wardell
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
2 shared publications - Allison Mary Deal
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
2 shared publications
Latest Publications
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22  (11) , 1885-1887
20 Years of Adolescent and Young Adult Oncology: Reflections and Aspirations
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22  (11) , 1885-1887
20 Years of Adolescent and Young Adult Oncology: Reflections and Aspirations
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22  (11) , 1986-1994
Comparing Outcomes: In-Person and Telehealth Oncology Visits
PURPOSE: Telemedicine offers significant benefits, but concerns regarding care quality persist. To inform future oncology telehealth policy, we compared subsequent health care use, patient-reported care quality, and communication outcomes between telehealth and in-person visits. METHODS: An observational cohort study (April 2022-October 2023) included patients age 21+ years with malignant neoplasms, a scheduled oncology visit, and cancer treatment initiated 6 months to 3 years before the study. Black adults and those with telehealth visits were oversampled. Pre- and post-visit telephone survey data were joined with electronic health record data and geocoded community characteristics. Outcomes included subsequent acute care events (emergency department visits and unplanned hospitalizations), follow-up visits, patient perceptions of whether their care needs were met, and communication quality via validated instruments, with Likert-scale responses. We estimated prevalence differences (PDs) in outcomes by visit type using propensity score–weighted generalized linear models that adjusted for patient socioeconomic, health, and census tract–level differences. RESULTS: After propensity score adjustments achieved covariate balance, 487 respondents (93 telehealth, 394 in-person) were included. Mean age was 64 (standard deviation = 13) years; 62% were female, 26% were Black, 82% had some college degree or more, and 25% reported fair/poor health. Follow-up in-person visits at 30 days were more frequent after telehealth (64%, 46%; PD = 0.18 [95% CI, 0.07 to 0.28]), with no differences at 7 or 14 days. Acute care use did not significantly differ at any time point. Quality and communication ratings were similar (PD range: 0.00-0.09), except for perceived privacy: 80% in-person, 67% telehealth, P < .01. CONCLUSION: Although mostly similar health care use and patient perceptions suggest telehealth as a viable oncology option, identified differences highlight the need to ensure privacy and evaluate when telehealth visits are most appropriate.
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22  (11) , 1986-1994
Comparing Outcomes: In-Person and Telehealth Oncology Visits
PURPOSE: Telemedicine offers significant benefits, but concerns regarding care quality persist. To inform future oncology telehealth policy, we compared subsequent health care use, patient-reported care quality, and communication outcomes between telehealth and in-person visits. METHODS: An observational cohort study (April 2022-October 2023) included patients age 21+ years with malignant neoplasms, a scheduled oncology visit, and cancer treatment initiated 6 months to 3 years before the study. Black adults and those with telehealth visits were oversampled. Pre- and post-visit telephone survey data were joined with electronic health record data and geocoded community characteristics. Outcomes included subsequent acute care events (emergency department visits and unplanned hospitalizations), follow-up visits, patient perceptions of whether their care needs were met, and communication quality via validated instruments, with Likert-scale responses. We estimated prevalence differences (PDs) in outcomes by visit type using propensity score–weighted generalized linear models that adjusted for patient socioeconomic, health, and census tract–level differences. RESULTS: After propensity score adjustments achieved covariate balance, 487 respondents (93 telehealth, 394 in-person) were included. Mean age was 64 (standard deviation = 13) years; 62% were female, 26% were Black, 82% had some college degree or more, and 25% reported fair/poor health. Follow-up in-person visits at 30 days were more frequent after telehealth (64%, 46%; PD = 0.18 [95% CI, 0.07 to 0.28]), with no differences at 7 or 14 days. Acute care use did not significantly differ at any time point. Quality and communication ratings were similar (PD range: 0.00-0.09), except for perceived privacy: 80% in-person, 67% telehealth, P < .01. CONCLUSION: Although mostly similar health care use and patient perceptions suggest telehealth as a viable oncology option, identified differences highlight the need to ensure privacy and evaluate when telehealth visits are most appropriate.
- 25 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
Predictive Risk Model for Early Post-Treatment Acute Care Use in Adolescent and Young Adult Patients With Cancer
PURPOSE: Adolescent and young adult (AYA) patients with cancer (ages 15-39 years at diagnosis) continue to have health care needs after completing treatment. Risk models to predict acute care events (ACEs) in this population may lead to earlier identification of high-risk populations. This study aimed to develop and validate a clinical risk model to predict ACEs in AYA patients with cancer during the early post-treatment period. METHODS: Using the University of North Carolina Lineberger Cancer Information and Population Health Resource, we identified AYAs diagnosed between 2006 and 2018 who were 2-5 years after diagnosis. The primary outcome was any ACE, defined as either hospitalization or emergency department (ED) visit. Patients were randomly assigned to development (70%) and validation (30%) cohorts. Logistic regression models were developed using stepwise inclusion of predictive variables. Model performance was evaluated using sensitivity, specificity, positive predictive value (PPV), and AUC. RESULTS: The study cohort included 7,393 patients (development = 5,276, validation = 2,217) with an average follow-up of 1.9 years. The most common cancers were breast (17%), thyroid (14%), and gynecologic (10%). Patients with ACEs (n = 3,572, 48%) were more frequently female, Black, and publicly insured. Defining high risk as the top 20% of scores, in the validation cohort, the selected model achieved an AUC of 0.76, a specificity of 0.94, a sensitivity of 0.34, and a PPV of 0.84. CONCLUSION: This is the first validated risk model to predict ACEs in AYA patients with cancer during the early post-treatment period. The model, designed for seamless electronic health record integration, enables early identification of high-risk patients, presenting opportunities for targeted interventions to reduce acute care use. Further validation across different health care systems is planned and will expand clinical applicability.
- 25 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
Predictive Risk Model for Early Post-Treatment Acute Care Use in Adolescent and Young Adult Patients With Cancer
PURPOSE: Adolescent and young adult (AYA) patients with cancer (ages 15-39 years at diagnosis) continue to have health care needs after completing treatment. Risk models to predict acute care events (ACEs) in this population may lead to earlier identification of high-risk populations. This study aimed to develop and validate a clinical risk model to predict ACEs in AYA patients with cancer during the early post-treatment period. METHODS: Using the University of North Carolina Lineberger Cancer Information and Population Health Resource, we identified AYAs diagnosed between 2006 and 2018 who were 2-5 years after diagnosis. The primary outcome was any ACE, defined as either hospitalization or emergency department (ED) visit. Patients were randomly assigned to development (70%) and validation (30%) cohorts. Logistic regression models were developed using stepwise inclusion of predictive variables. Model performance was evaluated using sensitivity, specificity, positive predictive value (PPV), and AUC. RESULTS: The study cohort included 7,393 patients (development = 5,276, validation = 2,217) with an average follow-up of 1.9 years. The most common cancers were breast (17%), thyroid (14%), and gynecologic (10%). Patients with ACEs (n = 3,572, 48%) were more frequently female, Black, and publicly insured. Defining high risk as the top 20% of scores, in the validation cohort, the selected model achieved an AUC of 0.76, a specificity of 0.94, a sensitivity of 0.34, and a PPV of 0.84. CONCLUSION: This is the first validated risk model to predict ACEs in AYA patients with cancer during the early post-treatment period. The model, designed for seamless electronic health record integration, enables early identification of high-risk patients, presenting opportunities for targeted interventions to reduce acute care use. Further validation across different health care systems is planned and will expand clinical applicability.
- Open Access
- 29 June 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1842108
Case Report: A case series on actionable genomic alterations guiding effective targeted therapy in rare sarcomas
Background: Advanced sarcomas have limited systemic therapy options, but genomic profiling can uncover actionable mutations. This case series illustrates the promise and limitations of next-generation sequencing (NGS) and targeted therapies in clinical practice across three sarcoma histologies. Case presentations: Case 1: A 36-year-old woman received local therapies for an angiosarcoma in her breast. Six months later, she developed osseous metastatic disease, and NGS revealed a GOPC-ROS1 fusion. She had a partial response to crizotinib. This ROS1 inhibitor and one course of radiation for oligometastatic progression controlled her disease for 12 months. Subsequent lines of therapy included pembrolizumab for high PD-L1 status, with suspected hyperprogression. Repotrectinib was trialed to overcome her ROS1 G2032R resistance mutation, but it had limited efficacy. She ultimately succumbed to her disease. Case 2: A 30-year-old woman with Neurofibromatosis Type 1 developed a high-grade, ALK-rearranged peripheral malignant nerve sheath tumor at her left antecubital fossa. Following resection, pulmonary metastases were identified. RNA transcriptome analysis revealed an EML4-ALK rearrangement. She had a prolonged partial response to alectinib. The ALK inhibitor and two courses of radiation for oligoprogression have continued to control her disease at 48 months. Case 3: A 51-year-old woman with uterine leiomyosarcoma developed pulmonary metastases shortly after completing adjuvant radiation. NGS revealed a BRCA2 deep deletion. After progressing on multiple lines of systemic therapies, her widely metastatic disease has been controlled for 62 months with niraparib and local therapies for oligoprogression. Discussion: Three patients with advanced sarcomas achieved partial responses to NGS-guided targeted therapies, with disease control lasting from 1 to over 5 years. Two cases involved novel, targetable mutations not previously identified in these sarcoma subtypes. However, the limitations of targeted therapies are highlighted by one patient’s lack of response to a novel ROS1 G2032R-directed treatment, and another patient’s repeated oligometastatic progression despite using an ALK inhibitor without resistance mutations. Simply suppressing a driver-mutation clone with targeted therapy may be insufficient for long-term disease control in sarcoma. Local therapies can be critical adjuvants in achieving improved outcomes for aggressive sarcomas. We recommend careful consideration of NGS testing for all sarcomas as we continue to explore their vast mutational landscape, response to targeted therapies, and mechanisms of resistance.
- 29 June 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1842108
Open AccessCase Report: A case series on actionable genomic alterations guiding effective targeted therapy in rare sarcomas
Background: Advanced sarcomas have limited systemic therapy options, but genomic profiling can uncover actionable mutations. This case series illustrates the promise and limitations of next-generation sequencing (NGS) and targeted therapies in clinical practice across three sarcoma histologies. Case presentations: Case 1: A 36-year-old woman received local therapies for an angiosarcoma in her breast. Six months later, she developed osseous metastatic disease, and NGS revealed a GOPC-ROS1 fusion. She had a partial response to crizotinib. This ROS1 inhibitor and one course of radiation for oligometastatic progression controlled her disease for 12 months. Subsequent lines of therapy included pembrolizumab for high PD-L1 status, with suspected hyperprogression. Repotrectinib was trialed to overcome her ROS1 G2032R resistance mutation, but it had limited efficacy. She ultimately succumbed to her disease. Case 2: A 30-year-old woman with Neurofibromatosis Type 1 developed a high-grade, ALK-rearranged peripheral malignant nerve sheath tumor at her left antecubital fossa. Following resection, pulmonary metastases were identified. RNA transcriptome analysis revealed an EML4-ALK rearrangement. She had a prolonged partial response to alectinib. The ALK inhibitor and two courses of radiation for oligoprogression have continued to control her disease at 48 months. Case 3: A 51-year-old woman with uterine leiomyosarcoma developed pulmonary metastases shortly after completing adjuvant radiation. NGS revealed a BRCA2 deep deletion. After progressing on multiple lines of systemic therapies, her widely metastatic disease has been controlled for 62 months with niraparib and local therapies for oligoprogression. Discussion: Three patients with advanced sarcomas achieved partial responses to NGS-guided targeted therapies, with disease control lasting from 1 to over 5 years. Two cases involved novel, targetable mutations not previously identified in these sarcoma subtypes. However, the limitations of targeted therapies are highlighted by one patient’s lack of response to a novel ROS1 G2032R-directed treatment, and another patient’s repeated oligometastatic progression despite using an ALK inhibitor without resistance mutations. Simply suppressing a driver-mutation clone with targeted therapy may be insufficient for long-term disease control in sarcoma. Local therapies can be critical adjuvants in achieving improved outcomes for aggressive sarcomas. We recommend careful consideration of NGS testing for all sarcomas as we continue to explore their vast mutational landscape, response to targeted therapies, and mechanisms of resistance.
- 12 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2600502
Challenging the Conventional Wisdom Around Doxorubicin in Soft Tissue Sarcoma
- 12 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2600502
Challenging the Conventional Wisdom Around Doxorubicin in Soft Tissue Sarcoma
- 7 May 2026
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 81  (5) , 231-240
Uterine Sarcomas: Clinical Management and a Review of Systemic Therapy
Importance: Uterine sarcomas are rare but aggressive tumors with high rates of recurrence and limited effective treatment options; a deeper understanding of their molecular and histologic diversity is critical to improving outcomes. Objective: To provide a comprehensive overview of clinical management and current systemic treatment strategies for uterine sarcomas. Specific histologic subtypes and molecular features are also reviewed. Evidence Acquisition: A thorough review of the literature was conducted using PubMed and clinical trial databases, with a focus on recent studies evaluating histology-specific management, molecular diagnostics, and novel systemic therapies across uterine sarcoma subtypes. Results: Uterine sarcomas comprise 3% to 5% of uterine malignancies and include multiple distinct subtypes such as leiomyosarcoma, low and high-grade endometrial stromal sarcoma, undifferentiated uterine sarcoma, and adenosarcoma. Each displays unique clinical behavior and molecular alterations that guide treatment. While surgery remains the foundation of management for early-stage disease, the role of adjuvant therapy is unclear and best guided by individual risk. In advanced disease, combination regimens such as doxorubicin and trabectedin have shown improved outcomes in the treatment of leiomyosarcomas. Targeted therapies, hormonal agents, and immunotherapy have variable activity across subtypes. Molecular diagnostics, including next-generation sequencing, are increasingly essential in diagnosis, prognostication, and treatment planning. Conclusions and Relevance: The landscape of uterine sarcoma treatment is rapidly evolving due to advances in molecular biology and emerging systemic therapies. Personalized management based on histology and molecular profiling, along with the development of subtype-specific clinical trials, will be essential in improving survival. Centralized, multidisciplinary care remains a cornerstone for patients with these rare tumors.
- 7 May 2026
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 81  (5) , 231-240
Uterine Sarcomas: Clinical Management and a Review of Systemic Therapy
Importance: Uterine sarcomas are rare but aggressive tumors with high rates of recurrence and limited effective treatment options; a deeper understanding of their molecular and histologic diversity is critical to improving outcomes. Objective: To provide a comprehensive overview of clinical management and current systemic treatment strategies for uterine sarcomas. Specific histologic subtypes and molecular features are also reviewed. Evidence Acquisition: A thorough review of the literature was conducted using PubMed and clinical trial databases, with a focus on recent studies evaluating histology-specific management, molecular diagnostics, and novel systemic therapies across uterine sarcoma subtypes. Results: Uterine sarcomas comprise 3% to 5% of uterine malignancies and include multiple distinct subtypes such as leiomyosarcoma, low and high-grade endometrial stromal sarcoma, undifferentiated uterine sarcoma, and adenosarcoma. Each displays unique clinical behavior and molecular alterations that guide treatment. While surgery remains the foundation of management for early-stage disease, the role of adjuvant therapy is unclear and best guided by individual risk. In advanced disease, combination regimens such as doxorubicin and trabectedin have shown improved outcomes in the treatment of leiomyosarcomas. Targeted therapies, hormonal agents, and immunotherapy have variable activity across subtypes. Molecular diagnostics, including next-generation sequencing, are increasingly essential in diagnosis, prognostication, and treatment planning. Conclusions and Relevance: The landscape of uterine sarcoma treatment is rapidly evolving due to advances in molecular biology and emerging systemic therapies. Personalized management based on histology and molecular profiling, along with the development of subtype-specific clinical trials, will be essential in improving survival. Centralized, multidisciplinary care remains a cornerstone for patients with these rare tumors.
- Open Access
- 27 March 2026
- Published by Springer Nature in Current Oncology Reports
- Vol. 28  (1)
Clinical Practice Guidelines for the Care of Adolescents and Young Adults (AYAs) with Cancer: a Scoping Review
Despite the increasing prevalence of cancer in adolescent and young adult (AYA) patient populations and a growing recognition of their unique care needs, there remains a lack of standardized guidelines on high-quality care. While various organizations and authors have put forth recommendations, these have yet to be integrated and harmonized. The purpose of this review was to capture relevant clinical practice guidelines on core elements that define quality care for AYAs with cancer, reviewing literature from 2006 through 2025. Eight studies met the inclusion criteria for clinical practice guidelines for the care of AYAs with cancer, many of which came from prominent oncology guidelines bodies, both nationally and internationally. Across the identified papers, 13 themes for AYA cancer care emerged, which were consolidated into practical recommendations. These themes were: 1) Raising Awareness, 2) Multidisciplinary Care, 3) Risk Assessment, 4) Innovative Models of Care, 5) Equity, 6) Psychosocial and Developmental Support, 7) Clinical Trials, 8) Reproductive Health, 9) Palliative Care, 10) Survivorship, 11) Access to Care, 12) Connections to Local Resources, and 13) Treatment Adherence. There are several high-quality clinical practice guidelines for AYA cancer care, summarized here into 13 themes. In this review, we discuss and contextualize these guidelines within the broader field of AYA oncology. By consolidating recommendations from diverse sources, we aim to provide a comprehensive resource for healthcare professionals, researchers, and policy makers to improve the quality of care for AYAs with cancer. The online version contains supplementary material available at 10.1007/s11912-026-01768-5.
- 27 March 2026
- Published by Springer Nature in Current Oncology Reports
- Vol. 28  (1)
Open AccessClinical Practice Guidelines for the Care of Adolescents and Young Adults (AYAs) with Cancer: a Scoping Review
Despite the increasing prevalence of cancer in adolescent and young adult (AYA) patient populations and a growing recognition of their unique care needs, there remains a lack of standardized guidelines on high-quality care. While various organizations and authors have put forth recommendations, these have yet to be integrated and harmonized. The purpose of this review was to capture relevant clinical practice guidelines on core elements that define quality care for AYAs with cancer, reviewing literature from 2006 through 2025. Eight studies met the inclusion criteria for clinical practice guidelines for the care of AYAs with cancer, many of which came from prominent oncology guidelines bodies, both nationally and internationally. Across the identified papers, 13 themes for AYA cancer care emerged, which were consolidated into practical recommendations. These themes were: 1) Raising Awareness, 2) Multidisciplinary Care, 3) Risk Assessment, 4) Innovative Models of Care, 5) Equity, 6) Psychosocial and Developmental Support, 7) Clinical Trials, 8) Reproductive Health, 9) Palliative Care, 10) Survivorship, 11) Access to Care, 12) Connections to Local Resources, and 13) Treatment Adherence. There are several high-quality clinical practice guidelines for AYA cancer care, summarized here into 13 themes. In this review, we discuss and contextualize these guidelines within the broader field of AYA oncology. By consolidating recommendations from diverse sources, we aim to provide a comprehensive resource for healthcare professionals, researchers, and policy makers to improve the quality of care for AYAs with cancer. The online version contains supplementary material available at 10.1007/s11912-026-01768-5.
- 26 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500950
Acute Care Events During Systemic Cancer Treatment: Moving From Risk Prediction to Clinical Decision Support Using a Two-Model Approach
PURPOSE: Acute care events (ACEs, emergency department visits and hospitalizations) are burdensome among patients with cancer—many are preventable. Prognostic risk models have not been consistently deployed as a preventive strategy. We convened a Clinical Advisory Panel (CAP) to address this translational bottleneck and develop clinically and statistically valid prognostic models to enable risk-stratified intervention. METHODS: We identified patients age 21+ years initiating cancer treatment at an academic center or affiliated sites. We extracted sociodemographic and clinical information from the EHR. Data were divided into training (50%), validation (25%), and test (25%) sets. Models were developed using constrained elastic-net logistic regression, with clinically informed coefficient constraints. RESULTS: In all, 4,697 patients were included, the mean age was 64 years, 71.9% were White, 21.8% had GI cancers, 21.7% had hematologic malignancies, 46.0% were Medicare insured, 77.6% were receiving chemotherapy, and 25.4% were receiving immunotherapy. We developed two models with our CAP, a baseline model predicting risk using a planned anticancer regimen and a follow-up model updating with drug dispensing and clinical changes. ACE in the previous month was the strongest predictor in both models (odds ratio [OR], 1.5, baseline model), with chemotherapy receipt (OR, 1.18), heart failure (OR, 1.22), abnormal international normalized ratio (OR, 1.30), and late-stage cancer (OR, 1.20) contributing. Both had acceptable statistical performance (C-statistic 0.71 and 0.70) and identified patients at the highest risk for ACE. CONCLUSION: We present a novel approach to ACE prediction among patients receiving cancer treatment using two models to anticipate patients' risk before treatment starts and then update based on clinical trajectory, facilitated by engagement of a CAP. To prevent ACE, risk-stratified interventions should focus on the factors we observed—optimizing comorbidities, proactively managing symptoms from high-toxicity regimens, or advanced disease.
- 26 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500950
Acute Care Events During Systemic Cancer Treatment: Moving From Risk Prediction to Clinical Decision Support Using a Two-Model Approach
PURPOSE: Acute care events (ACEs, emergency department visits and hospitalizations) are burdensome among patients with cancer—many are preventable. Prognostic risk models have not been consistently deployed as a preventive strategy. We convened a Clinical Advisory Panel (CAP) to address this translational bottleneck and develop clinically and statistically valid prognostic models to enable risk-stratified intervention. METHODS: We identified patients age 21+ years initiating cancer treatment at an academic center or affiliated sites. We extracted sociodemographic and clinical information from the EHR. Data were divided into training (50%), validation (25%), and test (25%) sets. Models were developed using constrained elastic-net logistic regression, with clinically informed coefficient constraints. RESULTS: In all, 4,697 patients were included, the mean age was 64 years, 71.9% were White, 21.8% had GI cancers, 21.7% had hematologic malignancies, 46.0% were Medicare insured, 77.6% were receiving chemotherapy, and 25.4% were receiving immunotherapy. We developed two models with our CAP, a baseline model predicting risk using a planned anticancer regimen and a follow-up model updating with drug dispensing and clinical changes. ACE in the previous month was the strongest predictor in both models (odds ratio [OR], 1.5, baseline model), with chemotherapy receipt (OR, 1.18), heart failure (OR, 1.22), abnormal international normalized ratio (OR, 1.30), and late-stage cancer (OR, 1.20) contributing. Both had acceptable statistical performance (C-statistic 0.71 and 0.70) and identified patients at the highest risk for ACE. CONCLUSION: We present a novel approach to ACE prediction among patients receiving cancer treatment using two models to anticipate patients' risk before treatment starts and then update based on clinical trajectory, facilitated by engagement of a CAP. To prevent ACE, risk-stratified interventions should focus on the factors we observed—optimizing comorbidities, proactively managing symptoms from high-toxicity regimens, or advanced disease.
- 11 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22  (7) , OP2501314-1152
Implementing Financial Toxicity Screening and Financial Navigation Among Adolescents and Young Adults With Cancer
- 11 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22  (7) , OP2501314-1152
Implementing Financial Toxicity Screening and Financial Navigation Among Adolescents and Young Adults With Cancer
- 1 May 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21  (5) , 710-719
Telephone Survey–Reported Perceptions of Telehealth Visits Among Black and Non-Black Patients Diagnosed With Cancer
PURPOSE: Empirical evidence underscores both benefits of telehealth visits and persistent disparities in use for Black adults. Guided by the Technology Acceptance Model, we evaluated perceptions regarding telehealth visits among Black and Non-Black adults receiving cancer care from two academic health systems. METHODS: Between April 2022 and October 2023, a survey was conducted among adult patients treated for cancer in the past 3 years. Survey recruitment was stratified by visit type (telehealth or in-person) and race. Before a scheduled oncology visit, respondents completed a telephone survey to assess their perceptions of usefulness, ease of use, and attitudes toward telehealth visits. Frequency differences were estimated using chi-square tests, and prevalence differences using logistic regression. RESULTS: The survey was completed by 773 respondents (42% Black) with a 15% response rate. Black respondents were younger and less likely to report male sex, being married, having a college education, comfortable income, or confidence in medical and e-literacy. Compared with Non-Black respondents, Black respondents perceived telehealth visits as less useful for determining health needs (37% v 48%) and asking questions (9% v 15%). They thought that telehealth visits were less easy with regard to understanding their health care provider (14% v 21%) and the ability to connect (23% v 30%). Black respondents expressed more concern about internet access (26% v 15%), access to electronic devices (17% v 9%), and finding assistance for connecting (24% v 12%). They also found telehealth visits to be less private (19% v 34%). CONCLUSION: Racial differences in telehealth ease of use and usefulness perceptions highlight the need for oncology practices to couple connectivity support with effective communication strategies to avoid disparities in oncology telehealth services.
- 1 May 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21  (5) , 710-719
Telephone Survey–Reported Perceptions of Telehealth Visits Among Black and Non-Black Patients Diagnosed With Cancer
PURPOSE: Empirical evidence underscores both benefits of telehealth visits and persistent disparities in use for Black adults. Guided by the Technology Acceptance Model, we evaluated perceptions regarding telehealth visits among Black and Non-Black adults receiving cancer care from two academic health systems. METHODS: Between April 2022 and October 2023, a survey was conducted among adult patients treated for cancer in the past 3 years. Survey recruitment was stratified by visit type (telehealth or in-person) and race. Before a scheduled oncology visit, respondents completed a telephone survey to assess their perceptions of usefulness, ease of use, and attitudes toward telehealth visits. Frequency differences were estimated using chi-square tests, and prevalence differences using logistic regression. RESULTS: The survey was completed by 773 respondents (42% Black) with a 15% response rate. Black respondents were younger and less likely to report male sex, being married, having a college education, comfortable income, or confidence in medical and e-literacy. Compared with Non-Black respondents, Black respondents perceived telehealth visits as less useful for determining health needs (37% v 48%) and asking questions (9% v 15%). They thought that telehealth visits were less easy with regard to understanding their health care provider (14% v 21%) and the ability to connect (23% v 30%). Black respondents expressed more concern about internet access (26% v 15%), access to electronic devices (17% v 9%), and finding assistance for connecting (24% v 12%). They also found telehealth visits to be less private (19% v 34%). CONCLUSION: Racial differences in telehealth ease of use and usefulness perceptions highlight the need for oncology practices to couple connectivity support with effective communication strategies to avoid disparities in oncology telehealth services.